ARGX241115P185000
- 0.00
- 0.000.00%
argenx SE Newsroom
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Argenx Upgraded at Wolfe on Myasthenia Gravis Dominance
Wolfe Research Upgrades Argenx SE(ARGX.US) to Buy Rating, Announces Target Price $697
Zai Lab, Argenx Receive Chinese Approval for Neuromuscular Drug Vyvgart Hytrulo
Argenx And Zai Lab Announce China's National Medical Products Administration Approved The Supplemental SBLA For VYVGART Hytrulo In Chronic Inflammatory Demyelinating Polyneuropathy
BofA Securities Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $670
Peering Into Argenx's Recent Short Interest
Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)
Truist Financial Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $660
This EBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Scotiabank Upgrades Argenx SE(ARGX.US) to Buy Rating, Raises Target Price to $715
Express News | Argenx SE : Scotiabank Raises to Sector Outperform From Sector Perform; Raises Target Price to $715 From $439
Argenx to Participate at Upcoming Investor Conferences
Stifel Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $707
Stifel Nicolaus Sticks to Their Buy Rating for Argenx Se (ARGX)
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $606 to $688
Argenx Price Target Raised to $639.00/Share From $547.00 by Wells Fargo
Argenx Is Maintained at Overweight by Wells Fargo
Argenx Shares Are Trading Higher. Multiple Firms Raised Their Respective Price Targets on the Stock.
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'